



UNIVERSITY OF LEEDS

This is a repository copy of *The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/116583/>

Version: Supplemental Material

Article:

Mackie, SL, Twohig, H, Neill, LM et al. (10 more authors) (2017) The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. *Journal of Rheumatology*, 44 (10). 161109. pp. 1515-1521. ISSN 0315-162X

<https://doi.org/10.3899/jrheum.161109>

© 2017 The Journal of Rheumatology. This is a pre-copy-editing, author-produced PDF of an article accepted for publication in *The Journal of Rheumatology* following peer review. The definitive publisher-authenticated version, Mackie, et al. (2017) *The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica*. *Journal of Rheumatology*, 44. 161109, is available online at:
<https://doi.org/10.3899/jrheum.161109>.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Table 1. Comparison of domains reported as being important to patients with polymyalgia rheumatica

Core Area	Domain*	Instrument used in published studies	Number of Studies of PMR Reporting Data on this Domain
Pathophysiological manifestations	Laboratory markers of systemic inflammation	ESR, CRP, IL-6, fibrinogen	30
	Elevation of upper limbs	Part of composite disease activity score	5
	Ability to carry out physical function tests	Grip strength, chair stand, 10-metre walk	1
	Ultrasonography	Synovitis, bursitis in shoulder and hip regions	4
	Physician global	VAS, NRS	14
Life Impact	Pain	VAS, NRS	17
	Morning stiffness	Duration (minutes), grade, severity (VAS)	26
	Fatigue	VAS	1
	Sleep disturbance	Not reported	0
	Patient global	VAS, NRS	9
	Physical functioning (in daily living)	HAQ	9
	Anxiety, depression	Part of SF36	2
	Health-related quality of life	SF36, VAS	3
Death	Mortality	Death registries, patient files.	1
Resource use	Not reported	Not reported	0
Adverse events	Adverse effects of medication	Standard methods for clinical trials	14

Outcomes measured in 35 clinical trials and longitudinal observational studies(9), grouped according to the OMERACT Filter 2.0 Framework.

* Bold typeface indicates highlighted in initial patient consultations (11)
 PMR, polymyalgia rheumatic; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; IL-6, interleukin-6; VAS, visual analogue scale; NRS, numeric rating scale; HAQ, Health Assessment Questionnaire; SF36, Medical Outcome Study Short Form 36. Adapted from published report(9).

